🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “cart” Clear

  1. Decartes-08

    Cartesian Therapeutics

    Myasthaenia Gravis

    phase 3 mab active

    1 trial

  2. Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

    Disc Medicine

    Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

    phase 3 small molecule active

    1 trial

  3. Microfracture

    Hospital Authority, Hong Kong

    Other Articular Cartilage Disorders

    phase 3 other active

    1 trial

  4. Placebo to Descartes-08, Descartes-08

    Cartesian Therapeutics

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  5. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  6. cART(TDF/AZT+3TC+LPV/r)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute HIV Infection

    phase 3 small molecule active

    1 trial

  7. ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  8. ASCT+CD7-CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CD7 Positive

    phase 2 small molecule active

    1 trial

  9. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  10. CART infusion

    Hospital Authority, Hong Kong

    B-cell Lymphoma Refractory

    phase 2 other active

    1 trial

  11. Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/​Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody

    The George Institute

    Multiple Myeloma

    phase 2 other active

    1 trial

  12. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  13. Descartes 08

    Cartesian Therapeutics

    Myeloma Multiple

    phase 2 mab terminated

    1 trial

  14. Descartes-08

    Cartesian Therapeutics

    Antisynthetase Syndrome

    phase 2 small molecule active

    1 trial

  15. Descartes-08

    Cartesian Therapeutics

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  16. Descartes-08

    Cartesian Therapeutics

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  17. Descartes-08

    Cartesian Therapeutics

    Childhood-onset Systemic Lupus Erythematous

    phase 2 small molecule active

    1 trial

  18. Descartes-11

    Cartesian Therapeutics

    Multiple Myeloma

    phase 2 mab terminated

    2 trials

  19. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  21. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  22. Varnimcabtagene autoleucel, BENDAMUSTINE, FLUDARABINE, DEXCHLORPHENIRAMINE, CYCLOPHOSPHAMIDE, PARACETAMOL, TOCILIZUMAB, ALLOPURINOL

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  23. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  24. ssCART-19

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources